Denmark's Novo Nordisk is to invest £115m in a science research centre in Oxford, providing resilience for the pharmaceutical industry after Brexit. The centre will hopefully employ around 100 academics researching new drugs, however manufacture and profit resulting from success will remain in Denmark. The European Medicines Agency currently based in London, is likely to move to the continent along with around 900 jobs. Click here to find out more.